CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
改造嵌合抗原受体（CAR）以提升肿瘤 CAR-T 细胞治疗安全性和降低毒性的策略
英文原题：Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
查看英文原题
Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞免疫治疗已在部分血液系统恶性肿瘤患者中显示出良好疗效，并催生了多种获批产品。尽管取得显著进展，这些产品仍面临重要挑战，包括潜在毒性，有时还会出现致命不良反应。CAR-T 治疗的毒性可源于细胞因子释放，也可由“靶向肿瘤、同时误伤肿瘤外正常组织”的毒性所致。本综述重点讨论靶向正常宿主组织所引起的意外脱靶效应，并介绍近期的安全策略，例如替换或增加CAR的不同组成部分、重新设计CAR结构以消除CAR-T 细胞的毒性作用；相关设计包括T细胞抗原偶联受体（TAC）、开关分子、自杀基因及人源化单克隆抗体。
展开英文摘要原文
Immune cell therapy with chimeric antigen receptor (CAR) T cells, which has shown promising efficacy in patients with some hematologic malignancies, has introduced several successfully approved CAR T cell therapy products. Nevertheless, despite significant advances, treatment with these products has major challenges regarding potential toxicity and sometimes fatal adverse effects for patients. These toxicities can result from cytokine release or on-target off-tumor toxicity that targets healthy host tissue following CAR T cell therapy.
The present study focuses on the unexpected side effects of targeting normal host tissues with off-target toxicity. Also, recent safety strategies such as replacing or adding different components to CARs and redesigning CAR structures to eliminate the toxic impact of CAR T cells, including T cell antigen coupler (TAC), switch molecules, suicide genes, and humanized monoclonal antibodies in the design of CARs, are discussed in this review.
论文信息
- 作者
- Sayadmanesh A、Yekehfallah V、Valizadeh A、Abedelahi A、Shafaei H、Shanehbandi D、Basiri M、Baradaran B
- 第一作者单位
- Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Advanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.Iran
- 通讯作者单位
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- International immunopharmacology2023 Dec
- 原文标识
- PubMed 37897950 · DOI 10.1016/j.intimp.2023.111093